Aerami Therapeutics's guest appearances

Aerami Therapeutics

CFO THOUGHT LEADER

Empowered Patient Podcast

Amolyt Pharma

Usama Malik

Sensus Healthcare

Bioxcel Therapeutics

Anixa Biosciences

Preston Klassen

Jay Venkatesan Angion

Cathy Miller

Joe Perekupka Brainsway

Suma Krishnan Krystal Biotech

Larry Wagner

Ryan Lanclos Esri

Anish Bhatnagar

Amy Dahm Cushing

Salma Jutt Orexigen

OwlTail

Anne Whitaker Aerami

Anne Whitaker

Anne Whitaker, CEO, Aerami Therapeutics talks about imatinib their inhaled treatment for the rare disease pulmonary arterial hypertension which could potentially be the first therapy on the market to actually reverse the disease.  First approved as a cancer therapy, imatinib stops the progression of the stiffening and thickening of the blood vessels in the lungs and is delivered using a breath-activated, Bluetooth enabled, hand-held nebulizer device delivering the drug centrally in the lung and in the peripheral area. @aeramiTx #inhaledtherapies #RespiratoryDiseases #PulmonaryArterialHypertension #PAH #imatinib Aerami.com Download the transcript here

Anne Whitaker, CEO, Aerami Therapeutics talks about imatinib their inhaled treatment for the rare disease pulmonary arterial hypertension which could potentially be the first therapy on the market to actually reverse the disease.  First approved as a cancer therapy, imatinib stops the progression of the stiffening and thickening of the blood vessels in the lungs and is delivered using a breath-activated, Bluetooth enabled, hand-held nebulizer device delivering the drug centrally in the lung and in the peripheral area. @aeramiTx #inhaledtherapies #RespiratoryDiseases #PulmonaryArterialHypertension #PAH #imatinib <a rel="noopener">Aerami.com</a> <a href="http://empoweredpatientradio.com/next-generation-inhaled-therapies-for-severe-respiratory-diseases-with-anne-whitaker-aerami-therapeutics-transcript-0" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Next Generation Inhaled Therapies for Severe Respiratory Diseases with Anne Whitaker Aerami Therapeutics

Mike Kaseta

Few megadeals within the past decade have received as many recurring kudos as the acquisition of Genzyme, of Cambridge, MA by France’s biggest pharmaceutical company, Sanofi. The marriage of Sanofi and Genzyme appears to have exceeded expectations, allowing all of those involved in minting the newly merged entity to rightfully keep a feather in their postmerger caps. Thus it was for Mike Kaseta, who in the wake of the merger found himself tasked with integrating the finance and IT functions of the two companies. “It’s probably the achievement that I’m most proud of in my career,” explains Kaseta, who, after nearly a decade climbing the finance ranks inside Sanofi, exited the giant pharmaceutical company to stake a claim inside the realm of early-stage biotech, where today he is CFO of Aerami Therapeutics. Looking back, Kaseta believes that the greatest lessons he gleaned from the Sanofi–Genzyme merger were people-related: “There was no iron fist. We listened to employees. We understood. In the end, we had no control deficiencies, no comments from our external auditors, and the integration occurred in a timely manner.” Looking forward, Kaseta says that raising money now tops his list of CFO priorities at Aerami. “We have to get our story out,” he adds. “We have to get it out to the right people and really engage with investors, allowing them to get as excited about our story as we are.” –Jack Sweeney Do you want to learn more about the experiences that shaped today’s finance leaders? GO PREMIUM with CFO Thought Leader and each quarter we will ship you our CFO Thought Leader Quarterly Magazine featuring profiles of 25 different CFOs (4 issues, per yr.). What’s more, become a PREMIUM member before February 1, 2020 and we’ll ship you THE CFO Yearbook 2020  featuring 100 CFO profiles. Go Premium today learn more

Few megadeals within the past decade have received as many recurring kudos as the acquisition of Genzyme, of Cambridge, MA by France’s biggest pharmaceutical company, Sanofi. The marriage of Sanofi and Genzyme appears to have exceeded expectations, allowing all of those involved in minting the newly merged entity to rightfully keep a feather in their postmerger caps. Thus it was for Mike Kaseta, who in the wake of the merger found himself tasked with integrating the finance and IT functions of the two companies. “It’s probably the achievement that I’m most proud of in my career,” explains Kaseta, who, after nearly a decade climbing the finance ranks inside Sanofi, exited the giant pharmaceutical company to stake a claim inside the realm of early-stage biotech, where today he is CFO of Aerami Therapeutics. Looking back, Kaseta believes that the greatest lessons he gleaned from the Sanofi–Genzyme merger were people-related: “There was no iron fist. We listened to employees. We understood. In the end, we had no control deficiencies, no comments from our external auditors, and the integration occurred in a timely manner.” Looking forward, Kaseta says that raising money now tops his list of CFO priorities at Aerami. “We have to get our story out,” he adds. “We have to get it out to the right people and really engage with investors, allowing them to get as excited about our story as we are.” –Jack Sweeney Do you want to learn more about the experiences that shaped today’s finance leaders? GO PREMIUM with CFO Thought Leader and each quarter we will ship you our CFO Thought Leader Quarterly Magazine featuring profiles of 25 different CFOs (4 issues, per yr.). What’s more, become a PREMIUM member before February 1, 2020 and we’ll ship you THE CFO Yearbook 2020  featuring 100 CFO profiles. Go Premium today <a href="https://gopremium.cfothoughtleader.com/" rel="nofollow" target="_blank">learn more</a>

555: Two Worlds One Career | Mike Kaseta, CFO, Aerami Therapeutics